KONEXT Secures 15 Billion KRW, Pharmarise Becomes Shareholder(venturesquare.net)
Writing language: KoreanRead in the original language
Plain summary
- Pharmarise joined KONEXT's 15 billion KRW Series C investment as a strategic investor.
- For bio founders, the point of interest is securing a partner who can support from clinical trials to commercialization, along with the investment amount.
- However, merely participating in the investment does not necessarily accelerate the development schedule; clear agreements on who takes on what tasks and by when are necessary to expect support beyond funding in actual collaboration.
Have you run into something like this? Tell us in a line or two what you did. You do not need to know the product.